Xvivo Perfusion (XVIVO.ST) Stock Analysis & AI Equity Report
Xvivo Perfusion (XVIVO.ST) overview
Xvivo Perfusion (XVIVO.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, Xvivo Perfusion reported revenue of SEK 812m and operating profit of SEK 93.0m; the year-end share price was 186.60 SEK and market capitalisation was SEK 5,878m. Xvivo Perfusion is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Xvivo Perfusion's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-27. Data will be refreshed during report generation.
About Xvivo Perfusion
XVIVO Perfusion AB develops and markets technologies and service solutions for organ preservation and transplantation. The company focuses on preserving, assessing, and transporting organs outside the body, with products and services for lungs, hearts, livers, and kidneys. It also provides organ recovery services, perfusion support, and communication tools for transplant clinics.
Generate the Xvivo Perfusion report
Xvivo Perfusion is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Xvivo Perfusion and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.